News

Under the agreement, Particle Sciences is responsible for design, formulation and cGMP supplies. Actavis will have responsibility for clinical testing, regulatory filings and marketing. Particle Sciences CEO Mark

This model is used for drug stratification and identification of personalized drug treatments for cancer patients. The work began through a joint project between Alacris and the SAP(R)

Currently, Azedra is in Phase II registrational trial in patients suffering from pheochromocytoma and paraganglioma. Progenics CEO Mark Baker said CPDC, and their host, McMaster University, serve as

SMA is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. It is caused by a genetic defect in the SMN1 gene, which codes

Once-daily PREZISTA is indicated for the treatment of HIV-1 in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations. PREZISTA is always taken with and at the

The patent with the latest date of expiry is 2030, without taking into account patent term extension. The three patent applications allowed by the USPTO cover composition of

Taclonex Ointment is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older. According to Symphony Health Solutions, brand

The approval is based on the data from an open label, multi-center Phase IV trial designed to evaluate the safety and immunogenicity of a single dose of Adacel

The acquisition elevates Actavis into a top-five position in the Thai generic pharmaceutical market, with leading positions in the ophthalmic and respiratory therapeutic categories and a strong cardiovascular